Therefore, therapeutic strategies targeting lung adenocarcinoma immune escape need to comprehensively consider how to activate and enhance the activity of CD8+ T cells to improve the effectiveness of immunotherapy, bringing about better treatment outcomes and quality of life for patients with lung adenocarcinoma (Wang et al. 2022a, b, c; Duan et al. 2021; Zhang et al. 2023a, b). The gene discussed is CD8A; the disease is lung adenocarcinoma.